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Abstract 
 
Objective 
To assess the cost-effectiveness of an amlodipine-based strategy compared to an atenolol-
based strategy in the treatment of hypertension in the UK and Sweden. 
 
Design 
A prospective, randomized trial complemented with a Markov model to assess long-term 
costs and health effects. 
 
Setting 
Primary care. 
 
Patients 
Patients with moderate hypertension and three or more additional risk factors. 
 
Interventions 
Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg 
adding bendroflumethiazide 1.25–2.5 mg and potassium as needed 
 
Main outcome measures 
Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life 
year gained. 
 
Results 
In the UK, the cost to avoid one cardiovascular event or procedure would be 18 965 €, 
and the cost to gain one quality-adjusted life year would be 21 875 €. The corresponding 
figures for Sweden were 13 210 € and 16 856 €. 
 
Conclusions 
Compared to the thresholds applied by NICE and in the Swedish National Board of 
Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost-
effective for the treatment of hypertension, compared to an atenolol-based regimen in the 
population studied. 
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Introduction 
Optimal first line therapy and subsequent sequencing of antihypertensive drugs has been 
controversial for decades. This is reflected in different recommendations made in recent 
guidelines worldwide. [1-4] Before 1995, almost all randomized trial evidence on 
hypertension management related to diuretics and to a lesser extent beta-blockers. [5] 
However newer drug classes were increasingly being used and have consequently been 
evaluated in major trials. Enthusiasm for any potential advantages of the newer agents (at 
least on surrogate end points) has been tempered in some situations by concerns over 
their increased cost. Despite the reality that the majority of hypertensive patients need at 
least two agents to reach currently-recommended targets, until recently no trial data were 
available to compare the benefits of newer combinations of drugs with the standard most 
commonly used regimen of a beta-blocker with a diuretic. 
 
The Blood-Pressure-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT-BPLA) randomized 19 257 patients to receive either amlodipine 5-10 mg 
adding perindopril  4 – 8 mg as needed to reach BP targets, or atenolol 50 – 100 mg  
adding bendroflumethiazide 1.25 – 2.5 mg and potassium as needed. 
Patients included in the trial were men and women aged between 40 and 79 years, with 
either untreated hypertension (a systolic blood pressure ≥160 mm Hg or a diastolic blood 
pressure ≥100 mm Hg) or treated hypertension with a systolic blood pressure ≥140 mm 
Hg or a diastolic blood pressure ≥90 mm Hg. Patients were also required to have at least 
three of the following risk-factors: male sex, age above 55 years, smoking, left 
ventricular hypertrophy, other abnormalities on electrocardiogram, type 2 diabetes, 
peripheral arterial disease, previous stroke or transient ischemic attack, microalbuminuria 
or proteinuria, a ratio of plasma total cholesterol to HDL-cholesterol of 6 or higher, or a 
family history of early CHD. The trial was stopped prematurely after a median of 5.5 
years due to a significant beneficial effect of the amlodipine-based regimen on all-cause 
mortality (HR 0.89, 95% CI:0.81-0.99). The hazard ratio (HR) for the primary endpoint 
(myocardial infarction (MI) including silent events and fatal CHD) was 0.90 (95 % 
confidence interval, CI: 0.79 – 1.02) in favour of the amlodipine-based regimen. There 
were also significant reductions in the number of fatal and non-fatal strokes (HR 0.77, 95 
% CI: 0.66 – 0.89), total cardiovascular events and procedures (HR 0.84, 95% CI: 0.78 – 
0.90) and in the incidence of new-onset diabetes in the amlodipine-based group (HR 0.70, 
95% CI:  0.63 – 0.78). [6] 
 
Looking only at the cost of medication, newer treatments (such as amlodipine and 
perindopril) are typically more expensive than their older comparators (such as atenolol 
and thiazides) but in ASCOT they induced superior preventive effects on all major CV 
outcomes.  In order to make a rational decision when allocating resources in health care, 
it is necessary to take potential savings due to decreased morbidity and mortality into 
consideration. If the net costs still indicate that the newer strategy adds costs, a formal 
estimation of the cost-effectiveness of the treatment is necessary. The scope of this study 
was to conduct an economic evaluation of ASCOT-BPLA. This prospective economic 
evaluation was a prespecified analysis of the trial. Analyses were conducted for the UK 
and Sweden, the two largest contributors in terms of numbers of patients in the trial.  
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Material and methods 
Two approaches were taken in the analysis of the cost-effectiveness of the amlodipine-
based regimen: A within-trial analysis estimating the costs and events avoided during the 
trial period; and a modelling approach extrapolating costs and the potential benefits of 
avoiding events on long-term survival and quality-adjusted survival over the life-time of 
the patients.  
 
In the within-trial analysis, resources used during the trial period (and being recorded on 
the case report forms) were multiplied by their unit cost, and an average cost per patient 
was estimated. Resources used included use of study drug, end-point related 
hospitalizations, non-endpoint related hospitalizations and concomitant medications using 
standard published sources for unit costs. [7-11] Prices are expressed in Euros (€), using 
the average exchange rates during 2006 to convert for British Pounds and Swedish 
Kronor to the € (1 € = 0,68 GBP, 9,25 SEK). [12] For a more in-depth description of the 
costing approach, please refer to our previously reported study of the lipid-lowering arm 
of ASCOT. [13] In the within-trial analysis, we used the average total number of events 
per patient during the trial as the measure of effectiveness. 
 
To estimate long-term cost and effects, a Markov model [14] consisting of six states was 
constructed: Event free, diabetes, MI, coronary revascularization, stroke, and death. The 
four event states (MI, diabetes, stroke and revascularization) are implemented as tunnel 
states to allow for differentiation of costs and lost utility over time. Patients in the event 
free state stand a risk of suffering any of the four events, which in the case of strokes and 
MI:s  may or may not be fatal. Patients in the event states either die or remain within their 
current state for the rest of the simulation. This means that only first events are explicitly 
incorporated in the model. Patients developing diabetes (or having diabetes at baseline), 
have a subsequent risk of developing MI, stroke or undergoing revascularization.  
 
The transition probabilities used in the model are derived from the clinical trial through 
survival modelling, with the exception of the risk of an event being fatal which was 
estimated through logistic regression. These data are available online.  Mortality 
following an event was estimated based on the entire trial sample (i.e. not estimated 
separately by treatment arm). This means that we are assuming no difference in mortality 
after an event for the two treatments. Any potential survival benefit is thus only caused 
by a difference in the risk of events. To avoid an underestimation of the mortality in 
higher age groups which were not represented in the trial, the model is programmed so 
that mortality does not fall below that of the general population (stratified by age and 
gender). [15] 
 
The cost of the study drug is based on the mean number of days each dose was prescribed 
during the trial period and the daily cost of the drug (see table 1). Because perindopril is 
not available on the Swedish market it was assumed to have the same relative price 
compared to the other study drugs as in the UK (0.81 € per 4 mg). We also conducted 
analyses where it was assumed to have the same price as the two most commonly used 
ACE-inhibitors in Sweden (ramipril 10 mg and enalapril 20 mg, 0.18 € and 0.05 € 
respectively).  
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Table 1. Drug costs (€) used in the analysis 
 UK Sweden 
Amlodipine 5 mg 0,69 0,54 
Amlodipine 10 mg 1,03 0,83 
Perindopril 4 mg 0,54 0,81 
Perindopril 8 mg 1,09 0,81 
Doxazosin GITS 4 mg 0,49 0,54 
Doxazosin GITS 8 mg 0,49 1,07 
Atenolol 50 mg 0,05 0,04 
Atenolol 100 mg 0,04 0,07 
BFZ/K+ 1.25 mg 0,05 0,13 
BFZ/K+ 2.50 mg 0,11 0,26 
 Source: Swedish Drug Tariff (FASS) and Monthly Index of Medical Specialities [10, 11] 
 
Costs for events were estimated by comparing the resource consumption during the year 
prior to the event to that one and two years following it (data available online). Health 
economic guidelines in Sweden and the UK differ in their view of costs caused by lost 
production (indirect costs) [16, 17] which Swedish guidelines recommend including, 
whereas the UK guidelines do not. Therefore only Swedish analyses incorporate indirect 
costs. This was based on a study of indirect costs and quality-of-life in Swedish ASCOT-
patients. [18]  Two measures of health outcomes were included in the model: life-years 
gained (LYG) based on the predicted survival in the two treatment groups and quality-
adjusted life years (QALY) gained. In the latter case each life-year is weighted according 
to the health status of the patients. The weights used (called utility weights) are normally 
between 1 and 0 where 1 represents a health state equal to perfect health and 0 to a health 
state equivalent to death. Event-free patients are assumed to have the same utility weights 
as individuals in the general population (adjusted for age and gender). [19, 20] To 
account for the effect of events, data from the above mentioned survey of Swedish 
patients was used. [18] This study indicated that patients with MI had moved back to 
their original utility level after one year, while no such improvement was seen in stroke 
patients. No data were collected for patients undergoing coronary revascularization. We 
therefore assume that they had a slightly smaller decrease in utility than the average 
patients with MI, based on results from another Swedish survey. [21] 
 
Uncertainty was incorporated into the model through probabilistic analysis using 2nd 
order Monte Carlo simulation. 1000 simulations where performed. In each of the 
simulations, each parameter was sampled from its underlying distribution. The 
distributions were estimated by performing non-parametric bootstrapping of each 
parameter. [22] Uncertainty was reported in the form of cost-effectiveness acceptability 
curves. [23]  
 
In the base-case, a cohort similar to that of the clinical trial was analysed (63 years of 
age, 19 % female, 27 % diabetic). Patients were assumed to be treated for 6 years, and 
followed for the remainder of their life. In the long-term model, costs and effects were 
discounted at 3.5 % per annum in the UK and 3 % per annum in Sweden in accordance 
with guidelines in the two countries. 
  
 group.bmj.com on July 13, 2010 - Published by heart.bmj.comDownloaded from 
 6
 
Results 
Table 2 shows the results from the within-trial analysis. As expected in the amlodipine-
based group, the cost of the study drugs was higher compared to the atenolol-based 
strategy, but there were lower costs for all other resource categories, thus offsetting 38 – 
50% of the drug costs during the 5.5-year trial period. 
 
Table 2. Mean costs, number of events and incremental cost-effectiveness during the trial 
period. 
UK Sweden  
Amlodipine-
based 
Atenolol-based Amlodipine-
based 
Atenolol-based 
Mean cost  (€) per 
patient 
    
Study drug 2440 (2418 ; 2462) 599 (590 ; 608) 2850 (2820 ; 2881) 1274 (1254 ; 1294) 
Outpatient visits 2440 (2425 ; 2455) 2525 (2509 ; 2543) 2240 (2227 ; 2254) 2318 (2303 ; 2334) 
Concomitant 
medications 
2167 (2127 ; 2207) 2418 (2375 ; 2459) 2396 (2353 ; 2438) 2649 (2604 ; 2693) 
DRG 
hospitalizations 
766 (718 ; 816) 1036 (976 ; 1097) 1068 (1000 ; 1136) 1448 (1364 ; 1531) 
Other 
hospitalizations 
3352 (3148 ; 3557) 3447 (3221 ; 3673) 2523 (2369 ; 2678) 2595 (2425 ; 2765) 
Total cost 11166  
(10942 ; 11391) 
10026  
(9775 ; 10277) 
11078  
(10889 ; 11267) 
10283  
(10071 ; 10496) 
Events per 
patient  
    
Primary endpoint1 0.047  
(0.043 ; 0.052) 
0.054  
(0.049 ; 0.059) 
0.047  
(0.043 ; 0.052) 
0.054  
(0.049 ; 0.059) 
All events and 
procedures 
0.216  
(0.203 ; 0.229) 
0.276  
(0.261 ; 0.291) 
0.216  
(0.203 ; 0.229) 
0.276  
(0.261 ; 0.291) 
Cost-
effectiveness* 
    
Cost to avoid one 
primary event 
161364  
(74752 ; 4327288) 
 112402  
(49597 ; 3106460) 
 
Cost to avoid one 
event or procedure 
18965  
(11591 ; 31855) 
 13210  
(7262 ; 23392) 
 
1Silent and non-silent MI and fatal CHD. 
Mean values and 95% confidence intervals. DRG = Diagnosis Related Group (potentially end-point related 
hospitalizations) 
* Compared with atenolol-based therapy 
 
Table 3 shows modelled lifelong predictions of costs, outcomes, and cost-effectiveness.  
The chief explanatory factor for the difference in survival and quality adjusted survival is 
the difference in discounting recommended in the UK and Swedish guidelines (3.5 and 
3% per year). This also affects the total predicted costs. The inclusion of indirect costs in 
the Swedish analysis is of minor importance due to the mean age of the population (63 
years) when included in the trial.   
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Table 3. Predicted per patient life-time costs (€), health outcomes and incremental cost-
effectiveness. 
 UK1 Sweden2 
 Amlodipine-
based 
Atenolol-based Amlodipine-
based 
Atenolol-based 
Costs     
Drug cost 3107 1069 4470 2480 
Event cost 2268 2471 3117 3361 
Indirect costs na na  215 278  
Total cost 5376 3540 7802 6119 
         
Health outcomes         
Life-expectancy 11.69 11.59 12.49 12.37 
Quality adjusted life-
expectancy 
8.84 8.76 9.82 9.72 
         
Incremental cost-
effectiveness3 
        
Cost per LYG 17857   14022   
Cost per QALY gained 21875 
  
16856 
  
1Costs and effects discounted at 3.5% per annum 
2Costs and effects discounted at 3% per annum 
3Relative to atenolol-based regimen 
LYG = Life Years Gained; QALY = Quality Adjusted Life years 
 
The cost-effectiveness acceptability curve shown in figure 1 shows the probability, given 
our data that the amlodipine-based strategy is cost-effective for different levels of 
willingness-to-pay to gain one QALY. The difference between the UK and Sweden is 
once again mainly due to the difference in discount rates, where the higher rate used in 
the UK leads to a lower valuation of future cost offsets and health gains compared to 
Sweden, and thus a lower probability of the strategy being considered cost-effective. 
 
<Figure 1 – CEAC > 
 
The assumptions in the model were tested in one-way sensitivity analyses. These 
indicated that the most sensitive variable is the proportion of females in the population, 
followed by the discounting factor used (data available online). In an all-female 
population, the incremental cost-effectiveness ratio (ICER) was 32 000 € per QALY in 
the UK and 24178 € per QALY in Sweden. Factors such as the average age, changes in 
the costs caused by events and the utility reduction caused had very limited impact on the 
results, as had extrapolating the duration of the intervention beyond the trial period. 
Using the price of enalapril or ramipril as proxies for the price of perindopril in Sweden 
lead to lower cost-effectiveness ratios (5 964 € and 3 606 € per QALY gained), due to the 
low prices of these drugs (generic enalapril is the cheapest antihypertensive drug on the 
Swedish market). The introduction of generic amlodipine also have a large impact of the 
results. At a price of 0.10 € per day in Sweden and 0.15 € per day in the UK the cost to 
gain one QALY becomes 7 257 € and 8 372 € in the respective countries.  
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Discussion 
In the UK, our study indicates a cost of 18 695 € to prevent one cardiovascular event or 
procedure, or 21 875 € to gain one QALY during with six years of treatment with the 
amlodipine-based, compared with the atenolol-based regimen. This falls well below the 
threshold value of 20 000 GBP (29 000 €) per QALY included in the most recent NICE 
guidelines to indicate cost-effectiveness. [17]  The corresponding figures were 13 210 
and 16 856 € in Sweden, where the National Board of Health and Welfare has published 
guidance for prioritizations in cardiovascular medicine. [24] In this guidance an ICER 
below 100 000 SEK/QALY (11 000 €) was classified as low, and a ratio below 500 000 
SEK/QALY (55 000 €) as moderate. Using these criteria, the cost-effectiveness ratio in 
our Swedish analyses fall just above the ‘low’ threshold. 
 
There is reason to believe that the cost-effectiveness ratios reported here are somewhat 
overestimated. Although the model incorporates new-onset diabetes as an end-point, the 
costs associated with the microvascular complications due to diabetes are not included 
since they are likely to occur after the end of the trial. Diabetes is also associated with 
excess non-cardiovascular mortality, which is not incorporated here. Indeed, excluding 
the additional cost for diabetes has a very limited impact on the results of our model, 
leading to an increase in the ICER of about 100 €. Using the cost reported in patients with 
no or microvascular complications only (assuming macrovascular complications are 
captured in the events costs of our model) that was reported in the CODE-2 in Sweden 
(1762 €) gives an ICER of 16 450 €. This may still be an underestimation, as the largest 
cost increase in CODE-2 was observed for patients with both micro- and macrovascular 
complications. [25] Costs included were based on the data collected in the trial which has 
the advantage of giving very high internal validity. Some potentially important costs were 
not collected, and are thus omitted from the event costs. This includes costs for 
rehabilitation following a stroke and costs for admittance to nursing home facilities. 
Furthermore, with the expiration of the patent on amlodipine, drug prices have fallen. 
This will of course lead to even more beneficial cost-effectiveness ratios. For example, in 
our model, a reduction in the price of amlodipine by 30% would give a cost-effectiveness 
ratio of 17 000 €/QALY in the UK and 13 500 €/QALY in Sweden. Indeed, with the 
current price of 0.10 € per day for amlodipine in Sweden and 0.15 € in the UK the cost 
effectiveness ratio would be 7 257 €/QALY in Sweden and 8 372 €7QALY in the UK. 
 
Some authors have argued for the inclusion of costs associated with increased survival 
(consumption minus production) to properly analyze the cost-effectiveness from a 
societal perspective. [26, 27] Such data are available for Sweden. [28] Including them in 
the analysis increases the cost-effectiveness ratio somewhat: 15 900 € per QALY gained. 
 
Conclusion 
Based on the threshold values for cost-effectiveness employed by the authorities in 
Sweden and the UK, an amlodipine-based treatment regimen appears to be cost-effective 
compared to an atenolol-based regimen in patients with moderate hypertension and 
additional risk factors. 
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Figure legends 
 
Figure 1. Cost-effectiveness acceptability curve indicating the probability that the 
amlodipine-based strategy is cost-effective compared to the atenolol-based strategy at 
different willingness-to-pay thresholds to gain one quality adjusted life-year.  
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Tables for online publication only 
Table A1. Costs (€) associated with the events in the model. 
 UK Sweden 
Difference 1st year after event 
to 1 year prior to the event  
  
Non-fatal MI 7964 (6903 ; 9027) 10521 (9563 ; 11479) 
Non-fatal stroke 5805 (4755 ; 6855) 7132 (6283 ; 7981) 
Coronary revascularization 
procedure 
8566 (7978 ; 9155) 10712 (10169 ; 11255) 
New onset diabetes 261 (-18 ; 540) 251 (14 ; 489) 
 
  
Difference 2nd year after event 
to 1 year prior to the event  
  
Non-fatal MI 1362 (687 ; 2039) 1400 (767 ; 2033) 
Non-fatal stroke 1060 (-43 ; 2163) 958 (102 ; 1813) 
Coronary revascularization 
procedure 
-26 (-558 ; 506) -352 (-883 ; 180) 
New onset diabetes 310 (-85 ; 705) 293 (-34 ; 619) 
   
Mean values and 95% confidence intrevals. MI = Myocardial infarction 
 
Table A2. Sensitivity analysis. 
 UK Sweden 
Variable Low value High value Low ICER High ICER Low ICER High ICER 
Fraction 
female 0 1 20340 32034 15676 24178 
Discount rate 0 0,05 15991 24797 12906 19871 
Longer 
treatment 
duration 6 10 18156 21912 14307 16856 
Start age 60 70 20232 23112 16076 17017 
Modification 
of costs 0,8 1,2 21428 22396 16367 17344 
Duration of 
excess cost 
after an events 2 5 21657 21912 16776 16856 
Reduction of 
utility 
(coronary 
revascularisati
on) 0 0,051 21822 22041 16798 16939 
Fraction 
diabetics 0 1 21782 21956 16742 16894 
Costs in €. ICER = Incremental cost-effectiveness ratio 
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